Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals Inc Cl A (NQ: RXRX )

8.760 -0.620 (-6.61%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,641,594
Open 9.300
Bid (Size) 8.050 (8)
Ask (Size) 8.090 (93)
Prev. Close 9.380
Today's Range 8.745 - 9.470
52wk Range 4.970 - 16.75
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Recursion Announces Pricing of $200 Million Public Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Pharmaceuticals Stock Is Diving Wednesday: What's Going On?
After the market close on Wednesday, Recursion said it intends to offer and sell $200 million worth of its common stock in an underwritten public offering. All of the shares are being offered by... 
Via Benzinga

Performance

YTD
-11.25%
-11.25%
1 Month
-2.56%
-2.56%
3 Month
-13.86%
-13.86%
6 Month
-18.13%
-18.13%
1 Year
+17.74%
+17.74%

More News

Read More
Recursion Announces Proposed Offering of Class A Common Stock
From Recursion Pharmaceuticals
Via GlobeNewswire
How Is The Market Feeling About Recursion Pharmaceuticals?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Recursion Pharmaceuticals Stock Is Moving Tuesday: What's Happening?
Via Benzinga
What's Going On With Recursion Pharmaceuticals Stock Monday?
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Recursion Gives Guidance on Seven Clinical Readouts within ~18 Months and Partnership Updates at Their Download Day
From Recursion Pharmaceuticals, Inc.
Via GlobeNewswire
Largest Clinical-Stage BioTech Drug Stocks Declined 6%
Via Talk Markets
NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
AI-Focused Drug Discovery Stocks Portfolio Down 4% W/e June 14th
Via Talk Markets
3 Stocks Under $10 Set to Quadruple by 2025: June Edition
Via InvestorPlace
AI-Focused Drug Discovery Stocks Portfolio Down 2% In May; Up 4% Last Week
Via Talk Markets
Recursion Pharmaceuticals Stock Could Be a 10-Bagger, but Only if It Comes Through on This Big Claim
Via The Motley Fool
Nvidia’s Golden Handshake: 3 Stocks Reaping the Rewards of an NVDA Alliance
Via InvestorPlace
1 Disruptive Biotech Stock to Buy Now, and 1 to Consider
Via The Motley Fool
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Owns These 2 AI Stocks. Should You?
Via The Motley Fool
Topics Artificial Intelligence
Exposures Artificial Intelligence
Is Recursion Pharmaceuticals Stock a Millionaire-Maker?
Via The Motley Fool
Power of Recursion OS on Display at Genome Scale in Nature Genetics Paper Detailing Potential Limitation of CRISPR Gene Editing Tool
From Recursion Pharmaceuticals
Via GlobeNewswire
2 Cathie Wood Biotech Stocks That Could Be Worth the Risk
Via The Motley Fool
Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week
Via Talk Markets
Recursion Appoints Robert Hershberg M.D., Ph.D, as New Chair of the Board
From Recursion Pharmaceuticals
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.